RxDoctor Payments Data

Saiful Kabir, MD

Pulmonary Disease · Anderson, INNPI 1598766321

Payments from drug & device makers

$3,304in general payments, 2019–2025

Across 195 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$552
  • AstraZeneca$482
  • Boehringer Ingelheim$284
  • Regeneron Healthcare Solutions, Inc.$244
  • Sanofi$204
  • Takeda Pharmaceuticals U.S.A., Inc.$203
  • plus $1K from 37 others

What the payments were for

  • Food & beverage$3,11994%
  • Education$1866%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,304 in reported general payments places this provider in the 55th percentile of 258 pulmonary disease providers in Indiana.

See all pulmonary disease providers in Indiana

Medicare billing

Part B allowed, 2024
$10,570
Medicare patients
169
Services billed
375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter455$332,694
Dupixent PenDupilumab75$312,513
Fasenra PenBenralizumab22$119,810
GlassiaAlpha-1-Proteinase Inhibitor11$111,259
Breztri AerosphereBudesonide/Glycopyr/Formoterol121$86,868
Breo ElliptaFluticasone/Vilanterol117$63,505
Spiriva RespimatTiotropium Bromide80$51,451
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr74$43,176
Stiolto RespimatTiotropium Br/Olodaterol Hcl65$33,355
SymbicortBudesonide/Formoterol Fumarate25$9,093
DuleraMometasone/Formoterol15$5,061
Roflumilast52$4,455
Fluticasone-SalmeterolFluticasone Propion/Salmeterol27$3,410
Albuterol Sulfate HfaAlbuterol Sulfate221$3,345
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$2,563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$552$439,376646 claims
Takeda Pharmaceuticals U.S.A., Inc.Glassia$203$111,25911 claims
AstraZenecaBreztri Aerosphere, Symbicort$482$95,961146 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$284$84,806145 claims
MerckDulera$14$5,06115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 258 pulmonary disease providers in Indiana.

Other pulmonary disease in Anderson

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →